Generate Biomedicines (NASDAQ:GENB) Sees Large Volume Increase - Time to Buy?

Key Points

• Generate Biomedicines’ trading volume rose 16% to approximately 836,226 shares, while the stock fell 13.9% to about $18.19 from its prior close of $20.38.
• Analyst sentiment remains broadly positive, with six Buy ratings, one Hold and one Sell; the consensus rating is “Moderate Buy” with an average price target of $25.40.
• The company missed quarterly earnings expectations, reporting a loss of $0.52 per share versus the $0.48 consensus estimate and revenue of $6.31 million. Institutional investors continued building positions, including a roughly $55.4 million purchase by Braidwell LP.

Generate Biomedicines Inc (NASDAQ:GENB - Get Free Report) saw unusually-strong trading volume on Wednesday . Approximately 836,226 shares changed hands during mid-day trading, an increase of 16% from the previous session's volume of 719,495 shares.The stock last traded at $18.1910 and had previously closed at $20.38.

Wall Street Analyst Weigh In

A number of research firms have recently commented on GENB. Morgan Stanley raised their price objective on shares of Generate Biomedicines from $20.00 to $22.00 and gave the company an "overweight" rating in a research report on Thursday, May 14th. Wall Street Zen cut shares of Generate Biomedicines from a "hold" rating to a "sell" rating in a research note on Saturday, August 8th. Weiss Ratings began coverage on shares of Generate Biomedicines in a report on Tuesday, August 11th. They issued a "sell (d)" rating for the company. Finally, HC Wainwright boosted their price target on shares of Generate Biomedicines from $16.00 to $25.00 and gave the company a "buy" rating in a research report on Friday, May 8th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $25.40.

Generate Biomedicines Trading Down 13.9%

The company has a market cap of $2.25 billion and a PE ratio of -11.03. The company's 50-day simple moving average is $15.19.

Generate Biomedicines (NASDAQ:GENB - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.52) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.04). The company had revenue of $6.31 million during the quarter. Equities research analysts forecast that Generate Biomedicines Inc will post -2.29 earnings per share for the current year.

Institutional Investors Weigh In On Generate Biomedicines

Hedge funds have recently made changes to their positions in the business. California State Teachers Retirement System purchased a new stake in Generate Biomedicines during the second quarter valued at about $96,000. Susquehanna International Group LLP purchased a new stake in shares of Generate Biomedicines during the second quarter valued at approximately $196,000. AXQ Capital LP bought a new position in shares of Generate Biomedicines in the second quarter worth approximately $218,000. Bank of New York Mellon Corp bought a new position in shares of Generate Biomedicines in the second quarter worth approximately $967,000. Finally, Braidwell LP purchased a new position in shares of Generate Biomedicines in the second quarter worth $55,398,000.

Generate Biomedicines Company Profile

Generate Biomedicines, Inc NASDAQ: GENB is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source